Respiratory and thoracic cancers:

Indications for: KRAZATI

In adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least 1 prior systemic therapy.

Adult Dosage:

Select patients based on the presence of KRAS G12C mutation in plasma or tumor specimens; if no mutation is detected, test tumor tissue. Swallow whole. 600mg twice daily until disease progression or unacceptable toxicity. Dose modifications for adverse reactions: see full labeling.

Children Dosage:

Not established. 

KRAZATI Warnings/Precautions:

Severe gastrointestinal reactions; monitor and manage using supportive care. Risk of QTc interval prolongation. Avoid in congenital long QT syndrome or concurrent QTc prolongation. CHF, bradyarrhythmias, electrolyte abnormalities: monitor ECGs and electrolytes prior to initiation, during, and as clinically indicated. Monitor LFTs prior to initiation, monthly for 3 months, or as clinically indicated. Monitor for new or worsening respiratory symptoms indicative of interstitial lung disease (ILD)/pneumonitis during therapy. Withhold if ILD/pneumonitis is suspected; permanently discontinue if no other causes of ILD/pneumonitis are identified. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).

KRAZATI Classification:

RAS GTPase (family) inhibitor.

KRAZATI Interactions:

Antagonized by strong CYP3A4 inducers (eg, rifampin); avoid. Potentiated by strong CYP3A4 inhibitors (eg, itraconazole); avoid concomitant use until adagrasib levels reach steady state (after ~8 days). Potentiates sensitive CYP3A, CYP2C9, CYP2D6, and P-gp substrates (eg, midazolam, warfarin, dextromethorphan, digoxin); avoid. Avoid concomitant other drugs known to prolong the QTc interval; if unavoidable, monitor ECG and electrolytes prior to initiation, during, and as clinically indicated.

Adverse Reactions:

Nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, decreased appetite, lab abnormalities (decreased lymphocytes, decreased hemoglobin, decreased platelets, increased AST/ALT, decreased sodium, increased creatinine, decreased albumin, increased lipase, decreased magnesium, decreased potassium).

Generic Drug Availability:


How Supplied:

Tabs—120, 180